Tegavivint for the Treatment of Relapsed or Refractory Leukemia

Summary

This phase I trial is to find out the best dose and side effects of tegavivint in treating patients with leukemia that has come back (relapsed) or does not response to treatment (refractory). Tegavivint may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving tegavivint in combination with decitabine may help control the disease.

Timeline

Start

2021-09-27

Primary completion

2027-02-02

Completion

2027-02-02

Drugs

Indications